Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCP2101
- Development stage
- Preclinical
- Lead developer
- Oncocross
- Modality
- Small Molecules
01
Overview
OCP2101 is a preclinical-stage drug candidate being developed by Oncocross Australia Pty Ltd for the treatment of oncology indications. The compound was identified using the company's proprietary RAPTOR AI™ platform, an AI-driven drug discovery engine that analyzes transcriptomic data to predict optimal drug-disease matches. Currently in the in vitro stage of development, OCP2101 is part of Oncocross's specialized pipeline, which focuses on leveraging gene expression signatures to address unmet needs in cancer therapy. Specific details regarding its molecular target and modality have not been publicly disclosed, though the platform typically identifies small molecule candidates for repositioning or novel therapeutic applications.
Beyond the preview
Go deeper on OCP2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OCP2101.